Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002163 · ClinicalTrials.gov registry record · Phase 3
A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex
A Phase 3 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002163: Completed Phase 3 study, sponsored by Glaxo Wellcome.
NCT00002163 is a Phase 3 study that has completed, run by Glaxo Wellcome. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002163, a Phase 3 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To evaluate the benefit of adding 1592U89 to current antiretroviral therapies for AIDS dementia complex and to assess the safety and tolerance of the treatment regimens.
Interventions
- DRUG Abacavir sulfate
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
What the finished NCT00002163 record still lists
NCT00002163 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Abacavir sulfate is the first listed.
NCT00002163 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002163 about?
NCT00002163 is a clinical study titled "A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex". To evaluate the benefit of adding 1592U89 to current antiretroviral therapies for AIDS dementia complex and to assess the safety and tolerance of the treatment regimens.
What is the current status of trial NCT00002163?
This trial is currently completed. It is a Phase 3 study.
What interventions are being tested in trial NCT00002163?
The interventions under investigation include: Abacavir sulfate (DRUG).
Who is sponsoring clinical trial NCT00002163?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.